Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES ANICURA IN CONNECTION WITH THE ACQUISITION OF DJURSKUKHUSET I JÄGARVALLEN
Mandate

VINGE ADVISES ANICURA IN CONNECTION WITH THE ACQUISITION OF DJURSKUKHUSET I JÄGARVALLEN

November 18, 2014

Vinge has advised AniCura in connection with the acquisition of Djursjukhuset i Jägarvallen, the oldest veterinary clinic in the county of Östergötland. The merger entails that AniCura has broadened its base of veterinary and medical facilities for pet owners in the region. AniCura is a leader in advanced veterinary care for dogs, cats and other companion animals. The company was founded on the notion of combining resources to provide better veterinary care. Established in 2011, AniCura is the first merger of companion animal hospitals in the Nordic region, and is currently the only Nordic veterinary care group exclusively focused on companion animals.

Vinge’s team consisted of responsible partner Jonas Bergström together with, among others, associates Gustav Jönsson and Ulrika Andersson.   

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024